Gufic Biosciences (GUFICBIO) Fundamentals 2026 — P/E 60.4x, Revenue Analysis | SniperIQ
Gufic Biosciences (GUFICBIO) is a India-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₹3,858 Crore, trading at ₹386.25 on the BSE. This SniperIQ fundamentals page covers Gufic Biosciences's valuation (P/E 60.4x, P/B 5.8x), profitability (net margin 6.8%), revenue (₹944 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Gufic Biosciences's market cap?
Gufic Biosciences (GUFICBIO) has a market capitalization of approximately ₹3,858 Crore, trading at ₹386.25 on the BSE. Market cap moves with the live share price.
What is Gufic Biosciences's P/E ratio?
Gufic Biosciences's trailing twelve-month P/E ratio is 60.4x, with a price-to-book (P/B) of 5.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Gufic Biosciences?
Gufic Biosciences runs a net profit margin of 6.8%, a gross margin of 45.5%, and an operating margin of 12.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Gufic Biosciences generate?
Gufic Biosciences reported revenue of ₹944 Crore for fiscal year 2026, with net income of ₹64 Crore and earnings per share (EPS) of 6.4. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Gufic Biosciences pay a dividend?
Gufic Biosciences offers a trailing dividend yield of about 0.0%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Gufic Biosciences financially healthy?
Gufic Biosciences carries a debt-to-equity ratio of 0.61x and a current ratio of 1.55x, with a market beta of -0.04. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Gufic Biosciences a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Gufic Biosciences (GUFICBIO) the key facts are: market cap ₹3,858 Crore, P/E 60.4x, revenue ₹944 Crore, 52-week range 267.5-447.85. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Gufic Biosciences's full fundamentals live
Get Gufic Biosciences's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.